BlinkLab

Blinklab Commences Partnership with Turning Pointe Autism Foundation for Clinical Study in Children with Autism in the US

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism, today announced that it initiated a clinical study in partnership with US based Turning Pointe Autism Foundation. The study will enroll up to one hundred children previously diagnosed with autism and one hundred children without an autism diagnosis. The data obtained during the course of this collaboration will be used to finalize the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.


Highlights

  • Strategic partnership initiated with US Based Turning Pointe Autism Foundation, to conduct a clinical study using AI-powered diagnostic tools developed for autism.
  • The study will involve up to two hundred children aiming to finalize the artificial intelligence/machine learning (“AI/ML”) algorithms and models for a larger FDA registration study planned for the second half of 2024.
  • This study aligns with regulatory preparations, setting the stage for an FDA registrational study.
  • The collaboration agreement ensures that any intellectual property developed as a direct result of the partnership will be owned by BlinkLab.
Founded in 2007, Turning Pointe Autism Foundation in Naperville, Illinois, was created to meet the specific and unique needs of students learning with autism. It offers individuals with autism between 5 to 22 years of age best practice programs to support their growth, development, and employment. To date, Turning Pointe’s commitment has had an impact on enhancing independence, communication, and social interactions among hundreds of children, teens, and adults. This collaboration between Turning Pointe and BlinkLab supports its vision to remain at the intersection of hope and innovation.

BlinkLab is proud to bring its innovative neurobehavioral tests to Turning Pointe’s programs. These tests, which can be easily administered via smartphone, are a game-changer in making diagnostic tools more accessible. BlinkLab’s initial focus will be on a pilot program involving students from Turning Pointe aimed at refining and improving the data collection and processing algorithms as well as our AI/Machine Learning models.

Henk-Jan Boele, CEO of BlinkLab commented:

“Our partnership with Turning Pointe is more than just collaboration. It is a major step toward fulfilling our mission to make well-established neurobehavioral testing clinically accessible and efficient. Turning Pointe’s dedication to quality education and support aligns perfectly with our goal of leveraging cutting-edge technology to better understand and assist individuals with autism. We are very excited about the possibilities that this collaboration offers for the advancement of autism diagnosis and care.”

Brian Leedman, Chairman of BlinkLab commented:

“I am excited to see that our first substantive news following our listing a few weeks ago is a collaboration with this prestigious group in the field of autism research in children. I anticipate many more important announcements such as these as we get closer to the commencement of our FDA registration study later this year”.

Study design and experimental setup

Neurobehavioral testing will be performed using the smartphone-based platform developed by BlinkLab. The tests will include general measurement of spontaneous and stimulus-evoked postural, head, facial, and vocal responses along with specific neurometric tests, including the acoustic startle response, prepulse inhibition, long-term habituation, and short-term habituation. Up to two hundred children will participate in the study. During the 15-minute smartphone evaluations, the children will watch an audio-normalized movie while the trials containing the auditory stimuli will be delivered via headphones. For each trial, computer vision algorithms will be used to track and record the position of the participant’s facial landmarks over time. The study will be performed in accordance with relevant guidelines and regulations and study protocol was reviewed and approved by the institutional review board of Princeton University (#13943) and Turning Pointe Autism Foundation.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.


BB1:AU
The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less

Revolutionising Mental Health Care Through Mobile Solutions

Green NVIDIA logo in a glossy 3D style on a dark background.

NVIDIA Facing Weak Demand for New Chip as Chinese Firms Turn to Homegrown Silicon

NVIDIA's (NASDAQ:NVDA) new RTX6000D chip, built to comply with US export curbs, is seeing little demand from major Chinese firms, sources familiar with the matter told Reuters this week.

Tests showed it lags the banned RTX5090, which remains widely available through gray market channels at less than half the RTX6000D’s price of roughly 50,000 yuan (around US$7,000).

NVIDIA currently faces a balancing dilemma in China, where the US has barred exports of its most advanced processors to limit Beijing’s artificial intelligence (AI) progress, forcing the company to design downgraded models.

Keep reading...Show less
Syntheia (CSE:SYAI)

Syntheia Announces Closing of Private Placement

Syntheia Corp. (CSE: SYAI) (syntheia.ai) (the "Company"), is pleased to announce that further to its press releases dated July 23, 2025, and September 2, 2025 the Company has closed the second tranche of its non-brokered private placement financing for gross proceeds of $709,677.48 through the issuance of 5,913,979 units (each, a "Unit") at a price of $0.12 per Unit (the "Offering").

Each Unit was comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.16 until September 2, 2030 (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.20 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

Keep reading...Show less
Circuit board forming a brain shape on a digital blue background.

Nebius Shares Soar on US$17.4 Billion Microsoft AI Deal

Nebius Group (NASDAQ:NBIS) surged on Tuesday (September 9) after announcing a multibillion-dollar deal with Microsoft (NASDAQ:MSFT) to provide dedicated artificial intelligence (AI) infrastructure.

Valued at US$17.4 billion over five years and expandable to US$19.4 billion if demand increases, the arrangement will see Nebius supply Microsoft with computing capacity from a new data center under construction in Vineland, New Jersey.

The news sent Nebius shares up 43.3 percent to US$91.75, their highest level on record.

Keep reading...Show less
OpenAI logo on a dark screen with a soft blue gradient background.

OpenAI Taps Broadcom to Build Custom AI Chips in Face of GPU Supply Concerns

OpenAI, the company behind ChatGPT, is reportedly set to begin large-scale production of its own artificial intelligence (AI) chips through a partnership with Broadcom (NASDAQ:AVGO).

Experts in the space see the move as a bid to cut reliance on chip giant NVIDIA (NASDAQ:NVDA) and ease the global shortage of processors driving platforms like ChatGPT.

The news came after Broadcom CEO Hock Tan told analysts in a September 4 call that the company had secured a fourth major customer that has committed to a US$10 billion order.

Keep reading...Show less
Person using laptop with generative AI, ChatGPT and other symbols floating between them.

10 Generative AI Stocks to Watch as ChatGPT Soars

The launch of OpenAI’s ChatGPT created a major buzz around artificial intelligence (AI) stocks.

ChatGPT is an AI chatbot software application that uses machine-learning techniques to emulate human-written conversations. This technology is called generative AI, and it's been making an impact on myriad industries, including marketing, security, healthcare, gaming, communication, customer service and software development.

The potential behind generative AI has been the primary driver behind a major stock rally that has helped the S&P 500 (INDEXSP:.INX) and Nasdaq Composite (INDEXNASDAQ:.IXIC) reach multiple new highs since 2023.

Keep reading...Show less
RemSense CEO and Managing Director Warren Cook

RemSense Eyes More Strategic Partnerships for Global Growth

RemSense (ASX:REM) is looking to secure more strategic partnerships as the company eyes global expansion, according to CEO and Managing Director Warren Cook.

“We have a strong pipeline of services to deliver to our existing clients that's going to take us right up through to the end of the year and into the early new year. For our global growth, we see partnerships as a critical part of our strategy to give us scale and capacity to grow throughout other parts of the region,” Cook said in an interview with the Investing News Network.

RemSense’s 3D visualisation technology — called virtualplant — is used by some major companies, including Woodside Energy Group (ASX:WDS,NYSE:WDS) and Chevron (NYSE:CVX).

Keep reading...Show less

Latest Press Releases

Related News

×